Lonza, WuXi Biologics, and Baxter Healthcare announce facility expansions and updates. Repligen reports revenue growth, while ...
New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.
Novo Nordisk said Thursday that it plans to eventually halt all of its human insulin pen production globally, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback